In management of diabetes, glucose lowering is the basic target treatment. Insulin essential to type 1 diabetes. Non-insulin therapy in 2 diabetes very diverse and continuously developing improve control prevent diabetes-related complications. recent 30 years, recommended specifications anti-diabetic drugs are high glucose-lowering efficacy, low risk hypoglycemia, less burden weight gain, cardi...

SGLT2 inhibitors are molecules able to reduce blood glucose levels and body weight, lower systolic pressure. They also exert important diuretic modulatory effects of renal hemodynamics, as well a series anti-inflammatory actions, thus contributing the cardiovascular burden in subjects with without type 2 diabetes. Such benefit mainly translates into reduced risk for hospitalization due heart fa...

Recently, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication that warns of an increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild to moderate glucose elevations (euglycemic DKA [euDKA]) associated with the use of all the approved sodium–glucose cotransporter 2 (SGLT2) inhibitors (1). This Communication was based on 20 clinical cases requiring...

INTRODUCTION Sodium glucose co-transporter 2 (SGLT2) inhibitors increase urinary glucose excretion (UGE) by reducing the renal threshold for glucose excretion, which results in decreased serum glucose concentrations in patients with type 2 diabetes mellitus (T2D). However, no study to date has determined whether larger increases in UGE after SGLT2 inhibitor treatment correspond to larger reduct...

Contemporary therapies to rationalize the hyperglycaemia in type 2 diabetes mellitus (T2DM) generally involve insulin-dependent mechanisms and lose their effectiveness as pancreatic b-cell function decreases to a greater extent. Kidney emerges out as a novel and potential target to trim down the T2DM. The filtered glucose is reabsorbed principally through the sodium glucose cotransporter-2 (SGL...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to reduce the risk of cardiovascular death or worsening heart failure (HF), and improve symptom burden, physical function quality life in patients with HF reduced ejection fraction. The mechanisms benefits SGLT2 inhibitors, however, remain unclear. In this substudy DEFINE-HF trial, randomized dapagliflozin placebo had lung fluid ...

OBJECTIVE To assess the safety and efficacy of dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes. RESEARCH DESIGN AND METHODS We treated 33 patients with sotagliflozin, an oral dual SGLT1 and SGLT2 inhibitor, or placebo in a randomized, double-blind trial assessing safety, insulin dose, glycemic control, and oth...

In today`s therapy of type 2 diabetes mellitus, SGLT2 inhibitors have taken their rightful place both due to positive hypoglycemic and outstanding cardiorenometabolic effects. Recent randomized clinical trials, such as DAPA HF, EMPEROR-Reduced EMPEROR-Preserved, show the benefits use in treatment patients with chronic heart failure without regard status mellitus so significantly expands range p...

BACKGROUND Sodium-glucose co-transporter-2 (SGLT2) inhibitors are new oral antidiabetic drugs that reduce hyperglycemia by promoting urinary glucose excretion. Glycosuria produced by SGLT2 inhibitors is associated with weight loss, mainly due to reduced fat volume. We investigated the effects of empagliflozin (selective SGLT2 inhibitor) and linagliptin (DPP-4 inhibitor) on steatohepatitis and f...